GAO Adulteration Report Points To Disconnect Among FDA Offices
This article was originally published in The Tan Sheet
Executive Summary
Food and drug attorneys critique the Government Accountability Office’s report on FDA’s efforts to counter economically motivated adulteration, which calls for greater cross-agency collaboration.
You may also be interested in...
AHPA Backs NDI Filing For Kratom, Experts Question FDA Enforcement
FDA regulation of kratom as an NDI is necessary to avoid untenable state regulations, says AHPA chief Michael McGuffin, adding the trade group's support to kratom experts' push to keep the herbal ingredient available. Experts also say salmonella issues currently linked to kratom could be an indirect result of FDA's import alert as noncompliant suppliers filled continued demand.
Supplement Industry Must Step Up As Adulteration Threat Grows – FDA
The supplement industry has not done enough to aid FDA in pursuing firms adulterating products with drugs or getting the message out about adulteration, the agency says. Increased vigilance is needed especially as bad actors become more sophisticated and expand their adulteration activities.